Table 1. Clinical-epidemiologic data of 31 disseminated histoplasmosis cases diagnosed in persons living with HIV/AIDS, University Hospital Dr. Miguel Riet Corrêa Jr., Rio Grande, Brazil, 2010–2019.
| Variable | Frequency, % (no./total no. participants) |
|---|---|
| M | 74 (21/31) |
| F |
26 (8/31) |
| Signs and symptoms | |
| Weight loss | 100 (31/31) |
| Fever (>37.8°C) | 100 (31/31) |
| Respiratory: cough and/or dyspnea | 100 (31/31) |
| Cutaneous: papular and/or ulcerated | 52 (16/31) |
| Neurologic: disorientation, focal deficit, paresthesia, confusion, headache and/or hemiplegia | 52 (16/31) |
| Digestive: abdominal distension and pain, diarrhea and/or nausea | 81 (25/31) |
| Hepatomegaly | 55 (17/31) |
| Splenomegaly | 81 (25/31) |
| Generalized lymph node enlargement |
35 (11/31) |
| Image exams | |
| Interstitial lung pattern | 55 (17/31) |
| Reticulonodular lung pattern | 32 (10/31) |
| Pulmonary nodules | 6 (2/31) |
| Mediastinal lymphadenopathy |
26 (8/31) |
| Blood assays | |
| Anemia | 100 (31/31) |
| Inflammatory marker* | 100 (31/31) |
| Liver damage marker† | 84 (26/31) |
| Tissue injury marker‡ | 87 (27/31) |
| Thrombocytopenia |
74 (23/31) |
| HIV assays | |
| CD4+ lymphocytes ≤100/mm3 | 71 (22/31) |
| CD4+ lymphocytes ≤50/mm3 | 48 (15/31) |
| HIV Viral load ≥50,000 copies |
90 (26/29) |
| First choice antifungal treatment | |
| None | 3 (1/31) |
| Amphotericin B deoxycholate | 81 (25/31) |
| Itraconazole |
16 (5/31) |
| Outcome after 12 months | |
| Alive | 65 (20/31) |
| Dead | 35 (11/31) |
*C-reactive protein increased. †Alkaline phosphatase increased. ‡Lactate dehydrogenase increased.